Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin b2 receptor-and angiotensin AT2 receptor-mediated mechanism

Hypertension

Volumn 63, Issue 4, 2014, Pages 768-773

  Koid, Suang Suang ^a,b   Ziogas, James ^b   Campbell, Duncan John ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

aliskiren; angiotensins; bradykinin; myocardial infarction

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALISKIREN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; BRADYKININ; BRADYKININ B2 RECEPTOR; ICATIBANT; VALSARTAN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HEART; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART WEIGHT; MEAN ARTERIAL PRESSURE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ALISKIREN; ANGIOTENSINS; BRADYKININ; MYOCARDIAL INFARCTION;

AMIDES; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; BRADYKININ; CARDIOTONIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; IMIDAZOLES; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2; TETRAZOLES; VALINE;

EID: 84897086970     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02902     Document Type: Article

References (49)

1. White CM, Greene L. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. J Manag Care Pharm. 2011;17(5 Suppl):S1-S15.
2. Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor block-ers in patients without heart failure. J Am Coll Cardiol. 2013;61:131-142.
3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097-3137.
4. Azizi M, Ménard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492-2499.
5. Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther. 2011;25:505-515.
6. Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. Hypertens Res. 2012;35:62-69.
7. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschöpe C. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075.
8. Parodi-Rullan R, Barreto-Torres G, Ruiz L, Casasnovas J, Javadov S. Direct renin inhibition exerts an anti-hypertrophic effect associated with improved mitochondrial function in post-infarction heart failure in diabetic rats. Cell Physiol Biochem. 2012;29:841-850.
9. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Renin inhibitor aliskiren improves impaired nitric oxide bioavail-ability and protects against atherosclerotic changes. Hypertension. 2008;52:563-572.
10. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118:984-993.
11. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51:1306-1311.
12. Campbell DJ, Zhang Y, Kelly DJ, Gilbert RE, McCarthy DJ, Shi W, Smyth GK. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol. 2011;38:623-631.
13. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension. 1998;32:84-88.
14. Kränkel N, Katare RG, Siragusa M, et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovasculariza-tion potential. Circ Res. 2008;103:1335-1343.
15. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension. 1998;31:39-44.
16. Giannella E, Mochmann HC, Levi R. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res. 1997;81:415-422.
17. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
18. Kositprapa C, Ockaili RA, Kukreja RC. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart. J Mol Cell Cardiol. 2001;33:1355-1362.
19. Regoli D, Plante GE, Gobeil F Jr. Impact of kinins in the treatment of cardiovascular diseases. Pharmacol Ther. 2012;135:94-111.
20. Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack JE 3rd, Deaton DW, Das DK. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation. 2000;102(19 Suppl 3):III346-III351.
21. Spillmann F, Van Linthout S, Schultheiss HP, Tschöpe C. Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. Curr Opin Nephrol Hypertens. 2006;15:22-29.
22. Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myo-cardial infarction in the rat. Circulation. 1997;95:1910-1917.
23. Hoshida S, Yamashita N, Kawahara K, Kuzuya T, Hori M. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation. 1999;99:434-440.
24. Kobara M, Tatsumi T, Kambayashi D, Mano A, Yamanaka S, Shiraishi J, Keira N, Matoba S, Asayama J, Fushiki S, Nakagawa M. Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J Cardiovasc Pharmacol. 2003;41:880-889.
25. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol. 2000;131:138-144.
26. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocar-dial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993;21:996-1003.
27. Jalowy A, Schulz R, Dörge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol. 1998;32:1787-1796.
28. Jugdutt BI, Balghith M. Enhanced regional AT(2)-receptor and PKC(epsilon) expression during cardioprotection induced by AT(1)-receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst. 2001;2:134-140.
29. Messadi-Laribi E, Griol-Charhbili V, Pizard A, Vincent MP, Heudes D, Meneton P, Alhenc-Gelas F, Richer C. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther. 2007;323:210-216.
30. Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the cardioprotective effects of AT 1 receptor antagonist in post-myocardial infarction remodeling. Life Sci. 2006;80:82-88.
31. Jugdutt BI, Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT 2 receptors during reperfused myocardial infarction. Mol Cell Biochem. 2004;260:111-118.
32. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP. Role of AT 2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension. 2002;40:244-250.
33. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31(1 Pt 2):349-355.
34. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodila-tion. J Clin Invest. 1999;104:925-935.
35. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension. 2000;35:1074-1077.
36. Katada J, Majima M. AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under fow conditions. Br J Pharmacol. 2002;136:484-491.
37. Hannan RE, Davis EA, Widdop RE. Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol. 2003;140:987-995.
38. Hiyoshi H, Yayama K, Takano M, Okamoto H. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension. 2004;43:1258-1263.
39. Messadi E, Vincent MP, Griol-Charhbili V, Mandet C, Colucci J, Krege JH, Bruneval P, Bouby N, Smithies O, Alhenc-Gelas F, Richer C. Genetically determined angiotensin converting enzyme level and myocar-dial tolerance to ischemia. FASEB J. 2010;24:4691-4700.
40. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian M P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive effcacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
41. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
42. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227-1234.
43. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmis-sions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125-1135.
44. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
45. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
46. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316.
47. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216:R1-R17.
48. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
49. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99:1926-1935.